Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-masked, actiVE-contRolleD, Multicenter Study to evaluAte Efficacy aNd safeTy of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial

Next Previous
X
Search
Trial Profile

Randomized, Double-masked, actiVE-contRolleD, Multicenter Study to evaluAte Efficacy aNd safeTy of Two Regimens of Intravitreal BI 771716 Against Pegcetacoplan in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration VERDANT Trial

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDR 202 (Primary) ; Pegcetacoplan
  • Indications Dry macular degeneration
  • Focus Therapeutic Use
  • Acronyms VERDANT
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 09 Dec 2024 Status changed from planning to not yet recruiting.
    • 06 Sep 2024 New trial record
    • 05 Sep 2024 According to a Boehringer Ingelheim media release, the preparation for the Phase II trial is now underway, with an expected start date in early 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top